The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 359:753-755 August 14, 2008 Number 7
NextNext

Tibolone and the Promise of Ideal Hormone-Replacement Therapy
Ghada El-Hajj Fuleihan, M.D., M.P.H.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Cummings, S. R.
-PubMed Citation
Since the mean life expectancy at menopause is 32.7 years, women spend more than one third of their lives in the estrogen-deficient postmenopausal state.1 Of the majority of menopausal women who have climacteric symptoms, 20% describe them as intolerable, and one third have such symptoms for up to 5 years.2 During her lifetime, one of every two women will have an osteoporotic fracture, one third will have coronary heart disease, one fifth will have a stroke or Alzheimer's disease, and one eighth will have breast cancer.

Whereas hormone-replacement therapy was once accepted as the ideal strategy for optimizing postmenopausal health . . . [Full Text of this Article]


Source Information

From the Calcium Metabolism and Osteoporosis Program, the American University of Beirut Medical Center, Beirut, Lebanon.




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.